alpha-CD30L mAb (Amgen)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Namealpha-CD30L mAb (Amgen)
Drug Alias Namealpha-CD30L (Amgen/CAT)alpha-CD30L (Immunex/Cambridge Antibody Technology)alpha-CD30L (Immunex/CAT)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsInflammationAutoimmune DiseasesLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmunex Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune LtdAmgen IncImmunex Corp
Active IndicationsN/A
Inactive IndicationsInflammationAutoimmune DiseasesLymphoma

Other Information

ATC CodeN/A
Related LinksN/A